Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | CA4 | P22748 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14282689 | 0.84 | TTBK1 (0.41) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL9610078 | 0.80 | CYP3A4 (0.37) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL25026499 | 0.77 | CYP3A4 (0.46) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL9911389 | 0.76 | CYP3A4 (0.33) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL9610079 | 0.76 | GAA (0.38) | CYP3A4TSHRALDH1A1MAPK1THRB | |
| SCHEMBL31257892 | 0.75 | SLC6A2 (0.42) | — | |
| SCHEMBL14355615 | 0.75 | CYP3A4 (0.37) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL9610093 | 0.75 | CYP3A4 (0.33) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL20929091 | 0.73 | CYP3A4 (0.42) | CYP3A4TSHRALDH1A1MAPK1ESR2 | |
| SCHEMBL29353640 | 0.73 | CYP3A4 (0.42) | CYP3A4TSHRALDH1A1MAPK1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | CYP3A4 2395/4885TSHR 2863/4885ALDH1A1 167/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | CYP3A4 673/4885TSHR 2111/4885ALDH1A1 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.